A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A
- Conditions
- Influenza A
- Interventions
- Registration Number
- NCT04683406
- Lead Sponsor
- Guangdong Raynovent Biotech Co., Ltd
- Brief Summary
This is a multi-center, randomized, double-blind, placebo-controlled, and active controlled clinical trial to assess the efficacy and safety of ZSP1273 tablets in the treatment of Acute Uncomplicated influenza A.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 750
-
Patients who are able to understand the study and comply with all study procedures, and willing to provide written informed consent/assent prior to the predose examinations appropriately.
-
Male or female patient s aged ≥ 18 to ≤ 64 years at the time of signing the informed consent/assent form
-
Patients with a diagnosis of influenza virus infection confirmed by all of the following
- Positive Rapid Antigen Test (RAT) with throat swabs;and
- Fever ≥ 38ºC (axillary) in the predose examinations or > 4 hours after dosing of antipyretics if they were taken;and
- At least one of the following general systemic symptoms associated with influenza are present with a severity of moderate or greater I. Headache II. Feverishness or chills III. Muscle or joint pain IV. Fatigue
- At least one of the following respiratory symptoms associated with influenza are present with a severity of moderate or greater I. Cough II. Sore throat III. Nasal congestion
-
The time interval between the onset of symptoms and the predose examinations is 48 hours or less. The onset of symptoms is defined as either
- Time of the first increase in body temperature (an increase of at least 1ºC from normal body temperature)
- Time when the patient experiences at least one general or respiratory symptom
-
Women of childbearing potential (WOCBP) who agree to use a highly effective method of contraception for 3 months after the first dose of ZSP1273 or oseltamivir
- Patients with severe influenza virus infection requiring inpatient treatment
- Patients aged ≥ 18 years with known allergy to oseltamivir (Tamiflu) or ZSP1273
- Patients unable to swallow tablets or capsules or any medical history in gastrointestinal that interferes with the absorption of drugs
- Patients who have received antiviral medication including peramivir, laninamivir, oseltamivir, zanamivir, rimantadine, umifenovir, or amantadine within 7 days prior to the predose examinations
- Patients who have received Chinese patent medicine or herbal medicine with antiviral effect within 7 days prior to the predose examinations
- Patients who have received Anti-influenzal prescription within 7 days prior to the predose examinations
- Subject who produces purulent sputum or has suppurative tonsillitis.
- White blood cells(WBC)>10.0×109/L at screening.
- Chest X - ray examination confirmed bronchitis,pneumonia,pleural effusion or pulmonary interstitial lesions.
- Patients who have experienced respiratory tract infection,Otitis media,nasosinusitis.
- Patients with severe or uncontrollable underlying diseases:blood disorders,severe chronic obstructive pulmonary disease(COPD),liver disorders(ALT or AST≥3 ULN,total bilirubin≥1.5 ULN),kidney disorders(serum creatinine>177μmol/L or 2mg/dL),chronic congestive heart failure(NYHA III-IV),mental disorders
- Immunodeficiency,including malignant tumor,organ or marrow transplant,human immunodeficiency virus [HIV] infection,or patients receiving immunosuppressant therapy 3 months prior to enrollment.
- Concomitant therapy with aspirin or salicylic acid.
- Patients weighing < 40 kg or morbid obesity(Body mass index [BMI]≥30kg/m2)
- Known history of alcohol abuse or drug abuse
- Pregnancy or breastfeeding at screening and during the study.All female subjects of childbearing potential must have a negative urine pregnancy test at screening and during the trial.
- Have received any other investigational products within 3 months prior to dosing.
- Patients who, in the opinion of the investigator, would be unlikely to comply with required study visits, self-assessments, and interventions
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Comparator Placebo to Oseltamivir Subjects received 5 doses of matching placebo of ZSP1273 and Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days Oseltamivir 75mg + ZSP1273 Placebo Oseltamivir(oral) Subjects received 10 doses of Oseltamivir at a dose of 75 mg twice daily (BID) with matching placebo of ZSP1273 orally once a day with approximately 12 hour (+/- 2) intervals, over 5 days ZSP1273 600 mg + Oseltamivir Placebo BID ZSP1273 600 mg Subjects received 5 doses of ZSP1273 at 600 mg once a day along with matching placebo of oseltamivir placebo orally twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days ZSP1273 600 mg + Oseltamivir Placebo BID Placebo to Oseltamivir Subjects received 5 doses of ZSP1273 at 600 mg once a day along with matching placebo of oseltamivir placebo orally twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days Placebo Comparator Placebo to ZSP1273 Subjects received 5 doses of matching placebo of ZSP1273 and Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days Oseltamivir 75mg + ZSP1273 Placebo Placebo to ZSP1273 Subjects received 10 doses of Oseltamivir at a dose of 75 mg twice daily (BID) with matching placebo of ZSP1273 orally once a day with approximately 12 hour (+/- 2) intervals, over 5 days
- Primary Outcome Measures
Name Time Method Time to Alleviation of Symptoms in Participants Randomized to ZSP1273 or Placebo Up to 14 days after first dose Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours.
Time to alleviation of symptoms was analyzed using the Kaplan-Meier(KM) method; participants who did not experience alleviation of symptoms were censored at the last observation time pointTime to Alleviation of Symptoms in Participants Randomized to ZSP1273 or Oseltamivir Up to 14 days after first dose Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours.
Time to alleviation of symptoms was analyzed using the Kaplan-Meier(KM) method; participants who did not experience alleviation of symptoms were censored at the last observation time point
- Secondary Outcome Measures
Name Time Method Change From Baseline in Virus RNA (RT-PCR) at Each Time Point in Participants Randomized to ZSP1273 or Oseltamivir Days 2, 4, 6 Nasopharyngeal swabs were obtained for viral quantitation.
Percentage of Participants Reporting Normal Temperature at Each Time Point in Participants Randomized to ZSP1273 or Placebo Up to 14 days after first dose Defined as the percentage of patients whose axillary temperature dropped to less than 37ºC after the initiation of study treatment
Percentage of Participants Reporting Normal Temperature at Each Time Point in Participants Randomized to ZSP1273 or Oseltamivir Up to 14 days after first dose Defined as the percentage of patients whose axillary temperature dropped to less than 37ºC after the initiation of study treatment
Percentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point in Participants Randomized to ZSP1273 or Oseltamivir Days 2, 4, 6 Influenza virus ribonucleic acid (RNA) was quantified from nasopharyngeal swabs.
Change From Baseline in Virus Titer at Each Time Point in Participants Randomized to ZSP1273 or Oseltamivir Days 2, 4, 6 Virus titer was quantified from nasopharyngeal swabs.
Change From Baseline in Virus RNA (RT-PCR) at Each Time Point in Participants Randomized to ZSP1273 or Placebo Days 2, 4, 6 Nasopharyngeal swabs were obtained for viral quantitation.
Time to Cessation of Viral Shedding Determined by Virus Titer in Participants Randomized to ZSP1273 or Oseltamivir Up to 6 days after first dose Time to Cessation of Viral Shedding Determined by Virus RNA in Participants Randomized to ZSP1273 or Oseltamivir Up to 6 days after first dose Percentage of Participants With Positive Influenza Virus Titer at Each Time Point in Participants Randomized to ZSP1273 or Placebo Days 2, 4, 6 Virus titer was quantified from nasopharyngeal swabs by tissue culture methods.
Time to Resolution of Fever in Participants Randomized to ZSP1273 or Oseltamivir Up to 14 days after first dose * Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for a duration of at least 12 hours
* Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time pointTime to Alleviation of Individual Symptoms in Participants Randomized to ZSP1273 or Placebo Up to 14 days after first dose Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of each symptom was defined as the time from the start of treatment to the start of the time period when the individual symptom was assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.Percentage of Participants With Positive Influenza Virus Titer at Each Time Point in Participants Randomized to ZSP1273 or Oseltamivir Days 2, 4, 6 Virus titer was quantified from nasopharyngeal swabs by tissue culture methods.
Change From Baseline in Virus Titer at Each Time Point in Participants Randomized to ZSP1273 or Placebo Days 2, 4, 6 Virus titer was quantified from nasopharyngeal swabs.
Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer in Participants Randomized to ZSP1273 or Placebo Up to 6 days after first dose This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 5. AUC was calculated using the trapezoidal method
Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer in Participants Randomized to ZSP1273 or Oseltamivir Up to 6 days after first dose This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 5. AUC was calculated using the trapezoidal method
Time to Cessation of Viral Shedding Determined by Virus Titer in Participants Randomized to ZSP-1273 or Placebo Up to 6 days after first dose Time to Alleviation of the Four Systemic Symptoms in Participants Randomized to ZSP1273 or Oseltamivir Up to 14 days after first dose Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of the 4 systemic symptoms was defined as the time between the initiation of the study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.
Time to alleviation of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.Time to Alleviation of the Three Respiratory Symptoms in Participants Randomized to ZSP1273 or Placebo Up to 14 days after first dose * Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat and nasal congestion) were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours
* Time to alleviation of the 3 respiratory symptoms was analyzed using the KM method; participants who did not experience alleviation of symptoms were censored at the last observation time pointChange From Baseline in Composite Symptom Score at Each Time Point in Participants Randomized to ZSP1273 or Placebo Up to 14 days after first dose * Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms)
* The composite symptom score is the total score of the 7 influenza symptoms as assessed by the participant at each time pointPercentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point in Participants Randomized to ZSP1273 or Placebo Days 2, 4, 6 Influenza virus ribonucleic acid (RNA) was quantified from nasopharyngeal swabs.
Time to Cessation of Viral Shedding Determined by Virus RNA in Participants Randomized to ZSP1273 or Placebo Up to 6 days after first dose Percentage of Participants Whose Symptoms Were Alleviated at Each Time Point in Participants Randomized to ZSP1273 or Placebo Up to 14 days after first dose Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Alleviation of symptoms was defined as all seven influenza-related symptoms assessed by the participant as absent (0) or mild (1)
Percentage of Participants With Influenza-related Complications in Participants Randomized to ZSP1273 or Oseltamivir Up to 14 days after first dose Change in EQ-5D-5L Up to 14 days after first dose Defined as the change from baseline in the index value and that in EQ VAS score as calculated from the EQ-5D-5L questionnaire.
Percentage of Participants Whose Symptoms Were Alleviated at Each Time Point in Participants Randomized to ZSP1273 or Oseltamivir Up to 14 days after first dose Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Alleviation of symptoms was defined as all seven influenza-related symptoms assessed by the participant as absent (0) or mild (1)
Time to Alleviation of the Four Systemic Symptoms in Participants Randomized to ZSP1273 or Placebo Up to 14 days after first dose Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of the 4 systemic symptoms was defined as the time between the initiation of the study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.
Time to alleviation of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.Time to Alleviation of the Three Respiratory Symptoms in Participants Randomized to ZSP1273 or Oseltamivir Up to 14 days after first dose * Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat and nasal congestion) were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours
* Time to alleviation of the 3 respiratory symptoms was analyzed using the KM method; participants who did not experience alleviation of symptoms were censored at the last observation time pointChange From Baseline in Composite Symptom Score at Each Time Point in Participants Randomized to ZSP1273 or Oseltamivir Up to 14 days after first dose * Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms)
* The composite symptom score is the total score of the 7 influenza symptoms as assessed by the participant at each time pointTime to Resolution of Fever in Participants Randomized to ZSP1273 or Placebo Up to 14 days after first dose * Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for a duration of at least 12 hours
* Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time pointTime to Return to Preinfluenza Health Status in Participants Randomized to ZSP1273 or Placebo Up to 14 days after first dose Time to Return to Preinfluenza Health Status in Adults Randomized to ZSP1273 or Oseltamivir Up to 14 days after first dose Defined as the time between the initiation of the study treatment and the return to normal activities of daily life. The return to normal activities of daily life is defined as the time when the subject assesses his/her activities as 10.Subjects with a baseline self-rated daily activity score of 10 are not included in this analysis.
Percentage of Participants With Influenza-related Complications in Participants Randomized to ZSP1273 or Placebo Up to 14 days after first dose Defined as the time between the initiation of the study treatment and the return to normal activities of daily life. The return to normal activities of daily life is defined as the time when the subject assesses his/her activities as 10.Subjects with a baseline self-rated daily activity score of 10 are not included in this analysis.
Time to Alleviation of Individual Symptoms in Participants Randomized to ZSP1273 or Oseltamivir Up to 14 days after first dose Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of each symptom was defined as the time from the start of treatment to the start of the time period when the individual symptom was assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.
Trial Locations
- Locations (76)
Third Military Medical University
🇨🇳Chongqing, Chongqing, China
Foshan First People's Hospital
🇨🇳Foshan, Guangdong, China
Huizhou Central People's Hospital
🇨🇳Huizhou, Guangdong, China
Jieyang People's Hospital
🇨🇳Jieyang, Guangdong, China
The First Affiliated Hospital Of Guangzhou Medical University
🇨🇳Guangzhou, Guangdong, China
Shenzhen Luohu Hospital Group Luohu People's Hospital
🇨🇳Shenzhen, Guangdong, China
Shenzhen People's Hospital
🇨🇳Shenzhen, Guangdong, China
Songgang People's Hospital
🇨🇳Shenzhen, Guangdong, China
Nanning First People's Hospital
🇨🇳Nanning, Guangxi, China
General Hospital of Liaohe Oilfield
🇨🇳Panjin, Liaoning, China
PKUCare luzhong Hospital
🇨🇳Zibo, Shandong, China
Xiamen Hospital of T.C.M
🇨🇳Xiamen, Fujian, China
Xiamen Zhongshan Hospital
🇨🇳Xiamen, Fujian, China
Qingyuan People's Hospital
🇨🇳Qingyuan, Guangdong, China
Shantou Central Hospital
🇨🇳Shantou, Guangdong, China
Yuebei People's Hospital
🇨🇳Shaoguan, Guangdong, China
Guizhou Provicial People's Hospital
🇨🇳Guiyang, Guizhou, China
First Hospital of Qinhuangdao
🇨🇳Qinhuangdao, Hebei, China
Nanjing Jiangning Hospital
🇨🇳Nanjing, Jiangsu, China
The Second Affiliated Hospital Of Nanchang University
🇨🇳Nanchang, Jiangxi, China
Shenyang Central Hospital Affiliated To Shenyang medical college
🇨🇳Shenyang, Liaoning, China
Binzhou Medical University Hospital
🇨🇳Binzhou, Shandong, China
Heze Municipal Hospital
🇨🇳Heze, Shandong, China
Shandong Energy Zaozhuang Mining
🇨🇳Zaozhuang, Shandong, China
Shanghai East Hospital
🇨🇳Shanghai, Shanghai, China
Shanxi Bethune Hospital
🇨🇳Taiyuan, Shanxi, China
The first People hospital of Yunnan Province
🇨🇳Kunming, Yunnan, China
Xuancheng People's Hospital
🇨🇳Xuancheng, Anhui, China
The First Affiliated Hospital of bengbu medical college
🇨🇳Bengbu, Anhui, China
Beijing Chaoyang Hospital,Capital Medical University
🇨🇳Beijing, Beijing, China
Beijing Ditan Hospital Capital Medical University
🇨🇳Beijing, Beijing, China
People's Hospital of Cuanjiang, Chongqing
🇨🇳Chongqing, Chongqing, China
Peking University Third Hospital
🇨🇳Beijing, Beijing, China
Quanzhou First Hospital
🇨🇳Quanzhou, Fujian, China
Fujian Provincal Hospital
🇨🇳Xiamen, Fujian, China
Guangdong Province Traditional Chinese Medical Hospital
🇨🇳Guangzhou, Guangdong, China
Nanfang Hospital
🇨🇳Guangzhou, Guangdong, China
Dongguan People's Hospital
🇨🇳Dongguan, Guangdong, China
Shunde University of Southern Medical University
🇨🇳Foshan, Guangdong, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
🇨🇳Guangzhou, Guangdong, China
Luoyang Central Hospital Affiliated To Zhengzhou University
🇨🇳Luoyang, Henan, China
Affiliated Hospital Zunyi Medical College
🇨🇳Zunyi, Guizhou, China
Huaihe Hospital of Henan University
🇨🇳Huaihe, Henan, China
Nanyang Central Hospital
🇨🇳Nanyang, Henan, China
The Second People's hospital of Nanyang
🇨🇳Nanyang, Henan, China
Nanyang First People's Hospital
🇨🇳Nanyang, Henan, China
The Third Affiliated Hospital of Nanyang Medical College
🇨🇳Nanyang, Henan, China
The Third Affiliated Hospital of Xinxiang Medical University
🇨🇳Xinxiang, Henan, China
Yiyang Central hospital
🇨🇳Yiyang, Hunan, China
Henan Provicial People's Hospital
🇨🇳Zhengzhou, Henan, China
Zhengzhou Sixth Hospital
🇨🇳Zhengzhou, Henan, China
Nanjing First Hospital
🇨🇳Nanjing, Jiangsu, China
Zhengzhou Central Hospital
🇨🇳Zhengzhou, Henan, China
Sir run run Hospital Nanjing Medical University
🇨🇳Nanjing, Jiangsu, China
Jiujiang University Affiliated Hospital
🇨🇳Jiujiang, Jiangxi, China
The Second Affiliated Hospital of Nanjing Medical University
🇨🇳Nanjing, Jiangsu, China
The Affiliated Hospital of Xuzhou Medical University
🇨🇳Xuzhou, Jiangsu, China
First Affiliated Hospital of Gannan Medical University
🇨🇳Ganzhou, Jiangxi, China
The Third Hospital Of Nanchang
🇨🇳Nanchang, Jiangxi, China
First Affiliated Hospital of Nanchang University
🇨🇳Nanchang, Jiangxi, China
Pingxiang People's Hospital
🇨🇳Pingxiang, Jiangxi, China
Shangyao People's Hospital
🇨🇳Shangyao, Jiangxi, China
The First Hospital Of Jilin University
🇨🇳Changchun, Jilin, China
Liaocheng People's Hospital
🇨🇳Liaocheng, Shandong, China
Jinan Central Hospital
🇨🇳Jinan, Shandong, China
Linyi People's Hospital
🇨🇳Linyi, Shandong, China
Chengdu Xinhua Hospital
🇨🇳Chengdu, Sichuan, China
Sichuan Provicial People's Hospital
🇨🇳Chengdu, Sichuan, China
General Hospital of Western Theater of PLA
🇨🇳Chengdu, Sichuan, China
West China Hospital of Sichuan University
🇨🇳Chengdu, Sichuan, China
The Third People's Hospital of Wuhou, Chengdu
🇨🇳Chengdu, Sichuan, China
The First Affiliated Hospital, Zhejiang University School of Medicine
🇨🇳Hangzhou, Zhejiang, China
Dazhou Central Hospital
🇨🇳Dazhou, Sichuan, China
Affiliated Hospital of North Sichuan College
🇨🇳Nanchong, Sichuan, China
Tianjin Medical University General Hospital
🇨🇳Tianjin, Tianjin, China
Ruian People's Hospital
🇨🇳Ruian, Zhejiang, China